|
|
|
| home > white papers > Maximize the ROI of Your Post-Approval Research - Bioclinica |
|
|
 WHITE PAPERS |
|
|
Bioclinica
|
|
Maximize the ROI of Your Post-Approval Research
|
|
Expenditures in post-approval (Phase IV) research are going up across
the pharmaceutical, biotech and medical device industries. Given the
resources you’ve committed to post-approval research, you may be
wondering if you’re getting the greatest possible return on your
investment.
Discover how to harness the power of post-approval
research to increase data collection, reduce resource burn, save money,
and maximize your ROI!
|
|
|
|
|
|
|
 |
News and Press Releases |
 |
U.S. Alliance Pharma Acquires U.K.-based LGC’s Drug Development Solutions (DDS) Business
Expands bioanalytical services to include many emerging areas worldwide.
More info >> |
|
 |
White Papers |
 |
|
Value-Added Processing and Quality By Design Principles Help Meet High-Quality Demands
West Pharmaceutical Services, Inc.
The current pharmaceutical market has faced a variety of challenges, including increasing expectations for quality from end-users and regulatory agencies driven by concern for patient safety. While pharmaceutical companies are working to assure that new quality and compliance paradigms are met, a balance must be achieved between the reality of managing costs in an effort to provide a product that meets the requirements of payers along with facilitating profitability in order to continue adequate business reinvestment.
More info >> |
|
|
|
